



ASX Announcement

Extension of time to repay loan

28 May 2020 – Race Oncology Limited (ASX:RAC) (**Race** or the **Company**) provides the following update to its announcement of 20 May 2020 in relation the limited recourse loan which RAC had previously granted to former Managing Director, Dr Peter Molloy.

Race has agreed that Dr Molloy has until 18 June 2020 to repay the limited recourse loan rather than 27 May 2020 as previously advised.

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

John Cullity, Chairman

john@biosynergypartners.com

Media contact:

Henry Jordan, Six Degrees Investor Relations

+61 431 271 538

henry.jordan@sdir.com.au

Dr Daniel Tillett, Chief Scientific Officer & Director

daniel.tillett@raceoncology.com